Question explored with the scientific record
Conversation so far
- 1 can severe symptoms of gout be misdiagnosed as heart issues
- 2 How often are gout cases mistakenly treated as coronary syndromes?
- 3 shortness of breath follow by sever gout flare, is it gout or heart issues?
- 4 how to cure high cholesterol
- 5 What are the risks of statins, and who benefits most vs least?
Answered on this page ↓
What are the risks of statins, and who benefits most vs least?
The short version: the evidence retrieved does not test your hypothesis. It contains no study comparing gout flare presentation to cardiovascular event presentation, and no study of misdiagnosis rates.
The evidence block is almost entirely about gout treatment—colchicine dosing [2], febuxostat timing [5], anakinra in kidney disease [9], and a new IL-1β antibody [3]. One case report describes pericarditis after a heart procedure [12], and another describes gout mimicking psoriatic arthritis [6], but neither addresses the question of gout flares being mistaken for heart attacks or angina. The 2021 Lancet review on gout [17] covers pathophysiology and management but does not discuss diagnostic confusion with cardiac conditions. There is no study here that measures how often a severe gout flare is misdiagnosed as acute coronary syndrome, pericarditis, or myocarditis, and no data on what fraction of patients with chest pain and elevated urate receive cardiac workup versus gout treatment.
Your hypothesis is plausible on mechanism—gout flares cause intense inflammation, chest wall pain from costochondral or sternoclavicular involvement can mimic cardiac pain, and elevated CRP and troponin can overlap. But the evidence retrieved does not test it. The gap itself matters: if this misdiagnosis is common, it would mean some patients get cardiac catheterization or antiplatelet therapy they do not need, while others get colchicine or NSAIDs for what is actually a cardiac event. Neither scenario is studied here.
My call: the hypothesis is mechanistically reasonable but unsupported by the evidence retrieved. Confidence: not clear—the question is unanswered by this retrieval, not answered in the negative.
Sources used 17
-
Effects of skim milk powder enriched with glycomacropeptide and G600 milk fat extract on frequency of gout flares: a proof-of-concept randomised controlled trial
A 3-month, three-arm randomized double-blind trial in 120 adults with recurrent gout shows that skim milk powder enriched with glycomacropeptide and G600 milk fat extract reduces gout flare frequency and improves pain compared with lactose control, suggesting potential dietary m…
DOI: 10.1136/annrheumdis-2011-200156 -
Oral Colchicine (Colcrys®)
This study evaluates the efficacy and tolerability of oral colchicine (Colcrys Ò) in treating acute gout flares and preventing future flares in patients, demonstrating its effectiveness compared to placebo.
DOI: 10.2165/11205470-000000000-00000 -
Efficacy and Safety of Firsekibart Compared to Etoricoxib for Gout Flares: A Phase 2, Multicenter, Open-label, Active-controlled, Randomized Non-inferiority Trial
A phase 2 multicenter randomized non-inferiority trial in Chinese adults with frequent gout flares found firsekibart (an anti-IL-1β antibody) provided non-inferior and superior pain relief at 72 hours compared with etoricoxib, and substantially reduced 12-week gout recurrence, w…
DOI: 10.1007/s40744-025-00790-6 -
Developing a provisional definition of flare in patients with established gout
This study aims to develop empirical definitions for a gout flare based on patient-reported features, validated against expert rheumatologist assessments, using data from 210 gout patients across eight international sites.
DOI: 10.1002/art.33483 -
Evaluation of febuxostat initiation during an acute gout attack: A prospective, randomized clinical trial
A 12-week, prospective randomized trial in Chinese patients with an acute gout attack evaluated initiating febuxostat at the start of an attack; it produced an early reduction in serum urate without significantly changing pain, recurrence, or adverse events compared with startin…
DOI: 10.1016/j.jbspin.2020.03.017 -
Gout Mimicking Psoriatic Arthritis Flare
This study presents a case of a 34-year-old man with a long history of psoriasis and inflammatory arthritis, ultimately diagnosed with coexisting gout and psoriatic arthritis, highlighting the complexities in diagnosis and treatment.
DOI: 10.1097/rhu.0b013e318259aa2e -
Development and First Validation of a Disease Activity Score for Gout
This study developed and first-validated a composite gout disease activity score (GAS) using data from the KING cohort, integrating serum urate, flares, tophi burden, joint inflammation, and patient- and physician-reported outcomes, with external validation in an independent sam…
DOI: 10.1002/acr.22844 -
Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study
A qualitative study using nominal group technique to identify facilitators and barriers to adherence to urate-lowering therapy among African-Americans with gout, revealing multiple behavioral, perceptual, and practical factors that differentiate high vs low adherers and informin…
DOI: 10.1186/ar4524 -
Effectiveness and safety of anakinra in gout patients with stage 4–5 chronic kidney disease or kidney transplantation: A multicentre, retrospective study
Anakinra provides rapid, effective relief of gout flares in patients with stage 4-5 CKD or kidney transplantation, with minimal short-term impact on renal function and a low infection risk, suggesting it may be a safe option when standard therapies are contraindicated, though ra…
DOI: 10.1016/j.jbspin.2018.03.015 -
Interleukin-37: associations of plasma levels and genetic variants in gout
Elevated plasma IL-37 is observed in asymptomatic hyperuricemia, intercritical gout, and chronic tophaceous gout, with 15 IL-37 gene variants showing phenotype-specific distributions across gout stages, implying a role for IL-37 in gout progression.
DOI: 10.1186/s13075-023-03188-3 -
Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan
A multidisciplinary consensus in Taiwan established 14 recommendations for managing gout and hyperuricemia, confirming hyperuricemia as the key risk factor and defining treatment targets, safety precautions, and lifestyle modifications.
DOI: 10.1111/1756-185x.13266 -
Acute Pericarditis after Percutaneous Coronary Intervention: A Case Report
A 58-year-old man developed acute pericarditis 6 hours after an unsuccessful percutaneous coronary intervention for chronic total occlusion of the left anterior descending artery, with relief after ibuprofen treatment and no recurrence after subsequent successful PCI.
DOI: 10.3390/medicina57050490 -
APPLICATION OF MONOCLONAL ANTIBODIES IN THE TREATMENT OF AUTOIMMUNE RHEUMATOLOGICAL DISEASES: MODERN APPROACHES AND PROSPECTS
Monoclonal antibodies substantially improve remission rates across major rheumatic diseases (RA, PsA, AS, SLE, AAV, gout, FMF, and sJIA), while highlighting safety, immunogenicity, and cost considerations, with therapeutic drug monitoring and biosimilars shaping personalized car…
DOI: 10.64582/ivit.uz.546 -
Adherence and Outcomes with Urate-Lowering Therapy: A Site-Randomized Trial
A large pragmatic, site-randomized trial showed that a pharmacist-led intervention using automated telephone reminders improved adherence to allopurinol and achievement of serum urate goals in gout patients initiating urate-lowering therapy, with benefits greatest in year 1 but …
DOI: 10.1016/j.amjmed.2018.11.011 -
Patients Prescribed Anakinra for Acute Gout Have Baseline Increased Burden of Hyperuricemia, Tophi, and Comorbidities, and Ultimate All-Cause Mortality
A retrospective study of veterans with gout found that those who received the IL-1 receptor antagonist anakinra had higher baseline hyperuricemia, tophaceous burden, East Asian descent, and comorbidity load, and exhibited higher all-cause mortality largely driven by comorbiditie…
DOI: 10.1177/1179544119890853 -
Gout, Hyperuricemia, and the Intestinal Microbiome
This narrative review synthesizes recent human and animal studies on the gut microbiome’s role in gout and hyperuricemia, highlighting microbial signatures and potential microbiome-targeted therapies (probiotics, prebiotics, butyrate) while detailing limitations and translationa…
DOI: 10.1007/s10753-025-02337-x -
Gout
This Seminar reviews the clinical presentation, pathophysiology, and management of gout, emphasizing urate-lowering therapy and nurse-led care.
DOI: 10.1016/S0140-6736(21)00569-9